Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL) today said that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorised generic of Omeprazole 40 mg capsules in the US healthcare system.
Omeprazole 40 mg is indicated for the treatment of acid related disease, including gastric ulcer and Zollinger- Ellison syndrome. The most common side effects for Prilosec are headache, diarrhea, and abdominal pain. Prilosec 40 mg had sales of $ 204.2 million in the US market.
“We welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialised immediately to all classes of trade in the US healthcare system under the Ranbaxy label,”said Jim Meehan, vice-president for sales and distribution, RPI. “We will offer this product as an affordable and accessible generic formulation to patients requiring this medication.”
RPI is engaged in sales and distribution of generic and branded prescription products in the US healthcare system.